Related Experiment Video
Updated: Nov 15, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Future directions in drug development in pancreatic cancer
Aurélien Lambert1, Thierry Conroy1, Michel Ducreux2
1Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Université de Lorraine, Nancy, France.
Abstract:
Pancreatic cancer is still one of the most lethal cancers with a reported 5-year relative survival rate of approximatively 9% and medical treatment remains a major challenge. Systemic treatment is recommended in every setting: resectable, borderline resectable, locally advanced and metastatic. Yet, few groundbreaking changes in practice have occurred in the last 30 years compared to other cancers and new treatments options are highly desirable. Most treatment approaches using chemotherapy have failed to improve patients' life expectancy and the few therapies finally found to have statistically significant benefit actually have modest clinical impact. It is becoming imperative to find new paths for improvement, such as encapsulated agents, new generation targeted therapies and treatments directed against the tumor microenvironment. We report here the new drugs of interest in pancreatic cancer and analyze the most recent failures.
Insights
Pancreatic cancer remains a deadly disease with limited treatment progress. New therapeutic strategies, including targeted therapies and tumor microenvironment treatments, are urgently needed to improve patient survival rates.
Area of Science:
- Oncology
- Gastroenterology
- Medical Research
Background:
- Pancreatic cancer has a low 5-year survival rate (approx. 9%), highlighting significant unmet medical needs.
- Current systemic treatments offer modest benefits and few advancements have occurred in the last three decades.
- Novel therapeutic approaches are crucial for improving outcomes in all stages of pancreatic cancer.
Purpose of the Study:
- To review emerging therapeutic agents for pancreatic cancer.
- To analyze recent treatment failures and identify areas for future research.
- To discuss innovative strategies targeting pancreatic cancer.
Main Methods:
- Literature review of recent clinical trials and research publications.
- Analysis of novel drug candidates and treatment modalities.
- Evaluation of treatment efficacy and impact on patient survival.
Main Results:
- Chemotherapy has shown limited success in extending patient life expectancy.
- Few therapies have demonstrated statistically significant, yet modest, clinical benefits.
- Emerging strategies include encapsulated agents, targeted therapies, and tumor microenvironment interventions.
Conclusions:
- There is a critical need for innovative treatments to overcome the challenges in pancreatic cancer therapy.
- Encapsulated agents, targeted therapies, and treatments modulating the tumor microenvironment show promise.
- Further research and development are essential to discover effective pancreatic cancer therapies.
